Aura Biosciences (NASDAQ:AURA) Shares Up 6.5% - Here's What HappenedMarket Beat·Aug 18 at 03:00 PMAURA+1.28%JPM+1.37%
Aura Biosciences releases corporate deck outlining bel-sar strategy in ocular oncologyPUBT·Aug 11 at 06:37 AMAURA+1.28%
Aura Biosciences, Inc. Q2 2026: Net loss $45.6M, EPS $(0.48) — 10-Q SummaryTradingView·Aug 11 at 06:21 AMAURA+1.28%
Aura Biosciences Q2 FY26 net loss widens to $45.64 million; R&D expense rises to $30.75 millionPUBT·Aug 11 at 06:05 AMAURA+1.28%
AURA: Shareholders approved all proposals, including a major increase in authorized common stockQuartr·Aug 5 at 09:36 AMAURA+1.28%
Aura Biosciences (AURA) Projected to Announce Quarterly Earnings on WednesdayMarket Beat·Aug 5 at 07:11 AMAURA+1.28%BNPQY-0.92%
Deckers Outdoor, Summit Therapeutics, Robert Half And Other Big Stocks Moving Lower In Friday’s Pre-Market Sessionbenzinga_article·Jul 24 at 07:04 AMSMMT-3.27%KRNY+0.92%
Aura Biosciences Reaffirmed at Buy with Unchanged $23 Target on Bel-sar’s Vision-Sparing PotentialTip Ranks·Jul 22 at 03:55 PMAURA+1.28%
Aura Biosciences director Jeremy Bender files initial beneficial ownership statementPUBT·Jul 8 at 03:11 PMAURA+1.28%
